Policy considerations for originator and similar biotherapeutic products-Reference-Cited by-同舟云学术

Policy considerations for originator and similar biotherapeutic products

Published:2016-10-09 Issue:1-4 Volume:18 Page:121-139
ISSN:1389-2827
Container-title:Pharmaceuticals Policy and Law
language:
Short-container-title:PPL

Author:

Grampp Gustavo¹,Kozak Robert W.²,Schreitmueller Thomas³

Affiliation:

1. Amgen Inc., Thousand Oaks, CA, USA

2. Bayer HealthCare LLC, Berkeley, CA, USA

3. F. Hoffmann - La Roche Ltd., Basel, Switzerland

Publisher

IOS Press

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference13 articles.

1. EuropaBio, Guideline to Biological Medicines. Available at: http//www.europabio.org/sites/report/ guide_to_biological_medicines_a_focus_on_biosimilar_medicines.pdf.

2. Drift, evolution, and divergence in biologics and biosimilars manufacturing;Ramanan;BioDrugs,2014

3. What's in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice;Steinman;J. Gen. Intern. Med.,2007

4. Physician Use of Brand Versus Generic Drug Names in 1993-1994 and 2003-2004;Kwo;Ann. Pharmacother,2009

5. Gewanter H. and Reilly M. (2015) Prescribing practices for biosimilars: questionnaire survey findings from physicians in Argentina, Brazil, Colombia and Mexico. GaBI J.; 4(4). Available at: http://gabi-journal.net/prescribing-practices-for-biosimilars-questionnaire-survey-findings-from-physicians-in-argentina-brazil-colombia-and-mexico.html?utm_source=GaBIJ+List&utm_campaign= c934a891a0-GJ+2015-4+anmt+V15L18-2&utm_medium=email&utm_term=0_34fdac12d2-c934 a891a0-91947769.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current state of biologic pharmacovigilance in the European Union: improvements are needed;Expert Opinion on Drug Safety;2019-02-27

2. Novel Constructs—Half-Life Extensions;Challenges in Protein Product Development;2018

3. Pharmacovigilance of Biosimilars: Global Experience and Perspective;Biosimilars;2018